Compare AstraZeneca plc (AZN) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Phillips 66 — how do they compare? AstraZeneca plc trades at $157.9 (market cap $248.14B), while Phillips 66 trades at $222.78 (market cap $89.52B). The key difference: AstraZeneca plc is far larger — about 2.8× Phillips 66's market cap, and Phillips 66 pays the higher dividend (2.26%). Which is the better fit depends on your goals.
| AZN | PSX | |
|---|---|---|
Market Cap | $248.14B | $89.52B |
Sector | Health | Energy |
52-Week High | $209.48 | $224.36 |
52-Week Low | $147.06 | $120.04 |
Enterprise Value | $275.41B | $105.99B |
Dividend Yield | 2.01% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
Phillips 66 (PSX) trades at $215.52, up 5.69% in the last session, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $208 and resistance at $219. Fundamentally, Q2 2026 EPS of $9.41 significantly beat estimates, driven by robust refining margins and high utilization rates. Recent news highlights the final investment decision for the $5 billion Western Gateway Pipeline joint venture, signaling growth in midstream operations.
Outlook remains positive with analyst consensus favoring Buy ratings (57%) and a $221.92 price target. Key opportunities include sustained refining strength and debt reduction, while risks involve volatile crude prices and geopolitical tensions affecting supply chains. Earnings growth and strategic projects underpin potential upside, but investors should monitor margin pressures and global energy dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
